Article
Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
Microbiology spectrum - 27 Apr 2022
Santos Bravo Marta, Tilloy Valentin, Plault Nicolas, Palomino Sonsoles Sánchez, Mosquera María Mar, Navarro Gabriel Mireia, Fernández Avilés Francesc, Suárez Lledó María, Rovira Montserrat, Moreno Asunción, Linares Laura, Bodro Marta, Hantz Sébastien, Alain Sophie, Marcos María Ángeles
Abstract excerpt
De novo mutations in the UL56 terminase subunit and its associated phenotypes were studied in the context of cytomegalovirus (CMV) transplant recipients clinically resistant to DNA-polymerase inhibitors, naive to letermovir. R246C was the only UL56 variant detected by standard and deep sequencing, located within the letermovir-resistance-associated region (residues 230-370). R246C emerged in 2/80 transplant...
Topics
- Acetates
- Antiviral Agents
- Cytomegalovirus
- Cytomegalovirus Infections
- Drug Resistance, Viral
- Humans
- Mutation
- Quinazolines
- Recurrence